Cargando…

Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review

Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Kiran, Shah, Nirali, Ghassemi, Fatameh, Ly, Carolyn, George, Teena, Lutz, Carla, Sumer, Huseyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926542/
https://www.ncbi.nlm.nih.gov/pubmed/35308830
http://dx.doi.org/10.1155/2022/9589600
_version_ 1784670260542046208
author Shah, Kiran
Shah, Nirali
Ghassemi, Fatameh
Ly, Carolyn
George, Teena
Lutz, Carla
Sumer, Huseyin
author_facet Shah, Kiran
Shah, Nirali
Ghassemi, Fatameh
Ly, Carolyn
George, Teena
Lutz, Carla
Sumer, Huseyin
author_sort Shah, Kiran
collection PubMed
description Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA's Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. Another milestone was achieved when allogeneic Mesenchymal Stem Cell- (MSC-) based therapy was approved by the EMA to treat Chrohn's disease in 2018. Allogeneic donor-derived MSC therapies in particular hold great promise and real hope because of their ‘off-the shelf' availability and accessibility for patients in need of urgent treatment. So far, thousands of clinical trials have explored the safety and efficacy of both autologous and allogeneic cell therapies, deeming them safe, however with varying degrees of efficacy. In the current pandemic, clinical trials have begun in many parts of the world to treat severe cases of COVID with MSCs. However, the risk of tissue rejection and the development of undesirable effects due to alloreactivity of allogeneic cells are currently not adequately addressed. Therefore, this warrants careful investigation and detailed reporting of such events by clinical researchers. This review aims at discussing the current landscape of approved allogeneic MSCs along with a few other cellular therapies. We explore any possible reactivity reported to inform the readers of any safety concern and on the efficacy of such therapies.
format Online
Article
Text
id pubmed-8926542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89265422022-03-17 Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review Shah, Kiran Shah, Nirali Ghassemi, Fatameh Ly, Carolyn George, Teena Lutz, Carla Sumer, Huseyin Stem Cells Int Review Article Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis. These cellular therapies have gained significant recognition in clinical research. The area has been further strengthened with the approval of Chimeric Antigen Receptor added on T cells (CAR-T) therapies by the regulatory authorities USA's Food and Drugs Administration (FDA), European Medical Agency (EMA), the Australian Therapeutic Goods Administration (TGA), and in many countries in 2017 to treat hematological cancers. Another milestone was achieved when allogeneic Mesenchymal Stem Cell- (MSC-) based therapy was approved by the EMA to treat Chrohn's disease in 2018. Allogeneic donor-derived MSC therapies in particular hold great promise and real hope because of their ‘off-the shelf' availability and accessibility for patients in need of urgent treatment. So far, thousands of clinical trials have explored the safety and efficacy of both autologous and allogeneic cell therapies, deeming them safe, however with varying degrees of efficacy. In the current pandemic, clinical trials have begun in many parts of the world to treat severe cases of COVID with MSCs. However, the risk of tissue rejection and the development of undesirable effects due to alloreactivity of allogeneic cells are currently not adequately addressed. Therefore, this warrants careful investigation and detailed reporting of such events by clinical researchers. This review aims at discussing the current landscape of approved allogeneic MSCs along with a few other cellular therapies. We explore any possible reactivity reported to inform the readers of any safety concern and on the efficacy of such therapies. Hindawi 2022-03-09 /pmc/articles/PMC8926542/ /pubmed/35308830 http://dx.doi.org/10.1155/2022/9589600 Text en Copyright © 2022 Kiran Shah et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Shah, Kiran
Shah, Nirali
Ghassemi, Fatameh
Ly, Carolyn
George, Teena
Lutz, Carla
Sumer, Huseyin
Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title_full Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title_fullStr Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title_full_unstemmed Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title_short Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
title_sort alloreactivity of allogeneic mesenchymal stem/stromal cells and other cellular therapies: a concise review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926542/
https://www.ncbi.nlm.nih.gov/pubmed/35308830
http://dx.doi.org/10.1155/2022/9589600
work_keys_str_mv AT shahkiran alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT shahnirali alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT ghassemifatameh alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT lycarolyn alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT georgeteena alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT lutzcarla alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview
AT sumerhuseyin alloreactivityofallogeneicmesenchymalstemstromalcellsandothercellulartherapiesaconcisereview